




16th Annual CCO/IMF Hematology Symposium: 2024 Myeloma Treatment Algorithm


Potential Newly Diagnosed Active Multiple Myeloma or Smoldering Multiple Myeloma




Newly Diagnosed Active Multiple Myeloma: Transplant Eligible




Newly Diagnosed Active Multiple Myeloma: Transplant Ineligible




Newly Diagnosed Active Multiple Myeloma: Special Settings




Multiple Myeloma at First Relapse



*Consider salvage ASCT in patients eligible for ASCT who have not had transplant before; consider second ASCT if eligible and had >36-month response duration with maintenance to first ASCT.



Multiple Myeloma at Second or Higher Relapse



ADC, antibody–drug conjugate; ASCT, autologous stem cell transplant; BCMA, B-cell maturation antigen; cilta-cel, ciltacabtagene autoleucel; CRAB, calcium elevation, renal insufficiency, anemia, bone abnormalities; Dara, daratumumab; Dex, dexamethasone; ERd, elotuzumab/lenalidomide/dexamethasone; EMD, extramedullary disease; EPd, elotuzumab/pomalidomide/dexamethasone; FLC, free light chain; ide-cel, idecabtagene vicleucel; IMiD, immunomodulatory drug; IRd, ixazomib/lenalidomide/dexamethasone; Isa, isatuximab; KCd, carfilzomib/cyclophosphamide/dexamethasone; Kd, carfilzomib/dexamethasone; KPd, carfilzomib/pomalidomide/dexamethasone; KRd, carfilzomib/lenalidomide/dexamethasone; Len, lenalidomide; mAb, monoclonal antibody; MM, multiple myeloma; PC, plasma cell; PCL, plasma cell leukemia; Pd, pomalidomide/dexamethasone; PI, proteasome inhibitor; Rd, lenalidomide/dexamethasone; SMM, smoldering multiple myeloma; TTP, time to progression; VCd, bortezomib/cyclophosphamide/dexamethasone; Vd, bortezomib/dexamethasone; VDT-PACE, bortezomib/dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide; VRd, bortezomib/lenalidomide/dexamethasone; VTd, bortezomib/thalidomide/dexamethasone.